Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

NCT01833520 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

DRUG: Ra-223 Dichloride

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]